CV outcome trials, such as EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS CV, have highlighted the efficacy of SGLT2 inhibitors in reducing HF-related outcomes in individuals with T2D [4–7]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.